pr-9986-preview.bioxconomy.com Open in urlscan Pro
2606:4700:4400::6812:2231  Public Scan

URL: https://pr-9986-preview.bioxconomy.com/
Submission: On October 18 via api from US — Scanned from DE

Form analysis 0 forms found in the DOM

Text Content

BioXconomy is part of the Informa Connect Division of Informa PLC
Informa PLC|ABOUT US|INVESTOR RELATIONS|TALENT
This site is operated by a business or businesses owned by Informa PLC and all
copyright resides with them. Informa PLC's registered office is 5 Howick Place,
London SW1P 1WG. Registered in England and Wales. Number 8860726.

AboutEventsAdvertise

Stay Updated

Stay Updated

Investment

RELATED TOPICS

 * VC/PE
 * Seed Funding

 * IPOs

RECENT IN INVESTMENT

See All
Overhead view of business people working and funding
Investment
$325 million Series C funding in its Arsenal (Biosciences)$325 million Series C
funding in its Arsenal (Biosciences)
byMillie Nelson
Sep 25, 2024
1 Min Read
photo of a sunrise over solar panels/building
Innovation
Inside five innovative research companies driving progress in oncology and
neurologyInside five innovative research companies driving progress in oncology
and neurology
Sep 21, 2024
9 Min Read
Innovation

RELATED TOPICS

 * Hubs
 * Academic Research

 * R&D Technology

RECENT IN INNOVATION

See All
photo of a sunrise over solar panels/building
Innovation
Inside five innovative research companies driving progress in oncology and
neurologyInside five innovative research companies driving progress in oncology
and neurology
Sep 21, 2024
9 Min Read
Mounajro
Innovation
GLP-1 boom causing pharma players FOMOGLP-1 boom causing pharma players FOMO
byMillie Nelson
Mar 25, 2024
2 Min Read
Partnering

RELATED TOPICS

 * Licensing
 * M&A

 * Deals
 * Best Practices

RECENT IN PARTNERING

See All
thumbnail
Partnering
Top five Asia biopharma deals: August 2024Top five Asia biopharma deals: August
2024
byRichard Daverman
Sep 15, 2024
4 Min Read
Abu Dhabi Global Healthcare Week 2024
Partnering
BioNTech: Partnerships are key to deliver drugs at scaleBioNTech: Partnerships
are key to deliver drugs at scale
byMillie Nelson
May 20, 2024
2 Min Read
Business Strategy

RELATED TOPICS

 * Scaling/Commercialization
 * Growth Strategy
 * ESG

 * Outsourcing
 * Legal

RECENT IN BUSINESS STRATEGY

See All
thumbnail
Business Strategy
Building successful teams in biotech: “The future is female and very
colorful”Building successful teams in biotech: “The future is female and very
colorful”
byMillie Nelson
May 7, 2024
2 Min Read


Sponsored By



LATEST NEWS


EYES ON ASIA: EISAI $1.5BN PACT, OCUMENSION & ALCON, TYK IPO AND MORE

Sep 18, 2024


TOP FIVE ASIA BIOPHARMA DEALS: AUGUST 2024

Sep 15, 2024


EYES ON ASIA: EPIMAB SELLS T-CELL, FUNDING FOR TARGETRX, HYGIEAI ON THE SIRNA
MARCH

Sep 7, 2024


EYES ON ASIA: UCB PORTFOLIO SALE, NAVIGATOR BAGS $100M, BORA BULKS OUT CDMO BIZ

Sep 1, 2024
Abu Dhabi Global Healthcare Week 2024
Partnering


BIONTECH: PARTNERSHIPS ARE KEY TO DELIVER DRUGS AT SCALE


BIONTECH: PARTNERSHIPS ARE KEY TO DELIVER DRUGS AT SCALE

BioNTech says it is necessary to forge partnerships with health systems to
successfully deliver personalized oncology vaccines at scale.

May 20, 2024
|
2 Min Read
Broken heart
Partnering
It’s not me, it’s you! Experts on when you should dump your CDMO
Experts on when you should dump your CDMO

Sep 22, 2023

CEO of Poseida, Kristin Yarema
VC/PE
Poseida: New CEO, same passion for allogeneic therapies
Poseida: New CEO, same passion for allogeneic therapies

Feb 26, 2024


Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation
and partnering directly in your inbox.
Stay Updated


C-SUITE CONVERSATIONS

See all
CEO of Poseida, Kristin Yarema
VC/PE
Poseida: New CEO, same passion for allogeneic therapies
Poseida: New CEO, same passion for allogeneic therapies

Feb 26, 2024

Dirk Lange
VC/PE
Testing times: MilliporeSigma talks CDMO competition
Testing times: MilliporeSigma talks CDMO competition

Oct 11, 2023





NEWS FROM APAC

See all
thumbnail
Partnering
Top five Asia biopharma deals: August 2024Asia biopharma deals: August 2024
byRichard Daverman
Sep 15, 2024
4 Min Read
thumbnail
Deals
Eyes on Asia: EpimAb sells T-cell, funding for TargetRx, Hygieai on the siRNA
marchEyes on Asia: News from EpimAb, TargetRx, Hygieai
byRichard Daverman
Sep 7, 2024
2 Min Read


BIO-Europe is the premier dealmaking event in Europe.

BIO-Europe November 4-6
Inside five innovative research companies driving progress in oncology and
neurology

BIO-Europe Spring 2023's therapeutic focus this year is on the latest innovation
in oncology and neurology. Leading international life science venture capital
firm TVM Capital Life Sciences has multiple investments in these areas. The firm
continues to build its portfolio with new investments from its Life Science
Innovation II fund.


PARTNERING DEALS

See all
Deals
Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more
Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more

Sep 18, 2024

Partnering
Top five Asia biopharma deals: August 2024
Asia biopharma deals: August 2024

Sep 15, 2024

Deals
Eyes on Asia: EpimAb sells T-cell, funding for TargetRx, Hygieai on the siRNA
march
Eyes on Asia: News from EpimAb, TargetRx, Hygieai

Sep 7, 2024

Deals
Eyes on Asia: UCB portfolio sale, Navigator bags $100m, Bora bulks out CDMO biz
Eyes on Asia: UCB portfolio sale, Navigator bags $100m, Bora bulks out CDMO biz

Sep 1, 2024




CONNECT

AboutAdvertise

JOIN US


Stay Updated

FOLLOW US



Copyright © 2024 Informa Connect Limited. Registered in England & Wales with
number 01835199, registered office 5 Howick Place, London, SW1P 1WG.

CCPA: Do not sell my personal info|Terms of Use|Code of Conduct: Events|Privacy
Policy|Cookie Policy